Park News
16th November 2007
Cellzome CEO appointed to the Board of the UK’s BioIndustry Association Cambridge, UK
Cellzome is pleased to announce the appointment of Tim Edwards, Chief Executive of the Company, to the Board of the BioIndustry Association, the UK’s biotech trade body. His appointment is effective from 1 January 2008.
Tim has more than 15 years' experience in the life sciences industry, with over 10 years in senior executive positions in leading biotech companies, both public and private. He has extensive business experience, particularly in developing and commercialising intellectual property arising from drug discovery research, and is a keen advocate of the UK’s biotechnology industry.
Tim Edwards, CEO of Cellzome, said:
"The BioIndustry Association is an important champion of the biotech industry in the UK. I am delighted to be involved in supporting the BIA’s activities in promoting the sector and in meeting its challenges.”– Ends –
About Cellzome Inc.
Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for screening and profiling of kinases in relevant cells and tissues. Cellzome’s emerging pipeline includes a small molecule Histamine H4 receptor antagonist, initially for asthma and allergic rhinitis, which is planned to begin clinical studies in 2008. Cellzome is applying its distinctive Kinobeads™ technology to the discovery and development of novel, selective kinase inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis, including PI3Kgamma and ZAP70. The Company has collaborations with Novartis on the discovery of target-lead pairs in a variety of disease areas, and with Johnson & Johnson for the discovery of novel medicines for the treatment of Alzheimer’s disease. Cellzome’s holding company is domiciled in the US and it employs about 85 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: www.cellzome.com.
About the BioIndustry Association
Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.
With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members’ interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society. For further information, please go to: www.bioindustry.org